Brief: Marksans Pharma Says FDA Post-Marketing Adverse Drug Experience Inspection Closed With Two Observations
07/08/2023 08:09
Aug 7 (Reuters) - Marksans Pharma Ltd MARK.NS :
* MARKSANS ANNOUNCES COMPLETION OF US FDA POST-MARKETING
ADVERSE
DRUG EXPERIENCE INSPECTION
* INSPECTION CLOSED WITH TWO OBSERVATIONS
* INSPECTION WAS CONDUCTED AT ITS GOA, VERNA MANUFACTURING
FACILITY
Source text for Eikon: ID:nNSE7TFBYC
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg